Merck said on Wednesday it would acquire eye disease drug developer EyeBio for up to $3 billion, as it looks to boost growth.

Was this article helpful?
YesNo

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Close Search Window